Literature DB >> 15937905

Bacterial infections in low-risk, febrile neutropenic patients.

Mallika Kamana1, Carmelita Escalante, Craig A Mullen, Susan Frisbee-Hume, Kenneth V I Rolston.   

Abstract

BACKGROUND: Accurate identification of low-risk, febrile neutropenic patients has become possible only recently. Many such patients are treated with oral antibiotics without hospitalization. To the authors' knowledge, data concerning the spectrum of bacterial infections in these patients are scarce, and collecting such data may have an impact on the choice of empiric oral regimen(s).
METHODS: Using the same risk-prediction and eligibility criteria, four studies of empiric therapy in low-risk, febrile neutropenic patients were conducted at the authors' institution. Based on that experience, patients also were entered on clinical pathways for outpatient therapy. For the current study, microbiologic data were pooled from those trials and clinical pathways (757 episodes) to describe the nature and spectrum of infections seen in this setting.
RESULTS: Unexplained fever occurred most often (58% of episodes), and both clinically documented and microbiologically documented infections were seen with equal frequency (21% of episodes, respectively). The most common clinical sites of infection were the upper respiratory tract, skin, and skin structure. Among microbiologically documented infections, monomicrobial, gram-positive infections accounted for 49% (with coagulase-negative staphylococci the most frequent); monomicrobial, gram-negative infections accounted for 36% (with Escherichia coli the most frequent); and 15% of infections were polymicrobial.
CONCLUSIONS: In this description of the spectrum of infections in the largest cohort of low-risk febrile neutropenic patients to date, episodes of unexplained fever were predominant, but gram-positive, gram-negative, and polymicrobial infections also were documented. Although these patients were at low risk for complications, they required broad-spectrum antibiotic therapy when they developed neutropenic fever.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15937905     DOI: 10.1002/cncr.21144

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  11 in total

1.  Outpatient treatment for people with cancer who develop a low-risk febrile neutropaenic event.

Authors:  Rodolfo Rivas-Ruiz; Miguel Villasis-Keever; Guadalupe Miranda-Novales; Osvaldo D Castelán-Martínez; Silvia Rivas-Contreras
Journal:  Cochrane Database Syst Rev       Date:  2019-03-19

2.  Clinical factors predicting bacteremia in low-risk febrile neutropenia after anti-cancer chemotherapy.

Authors:  Young Eun Ha; Jae-Hoon Song; Won Ki Kang; Kyong Ran Peck; Doo Ryeon Chung; Cheol-In Kang; Mi-Kyong Joung; Eun-Jeong Joo; Kyung Mok Shon
Journal:  Support Care Cancer       Date:  2010-10-08       Impact factor: 3.603

3.  Oral moxifloxacin for outpatient treatment of low-risk, febrile neutropenic patients.

Authors:  Kenneth V I Rolston; Susan E Frisbee-Hume; Shreyaskumar Patel; Ellen F Manzullo; Robert S Benjamin
Journal:  Support Care Cancer       Date:  2009-04-22       Impact factor: 3.603

4.  Etiology and clinical course of febrile neutropenia in children with cancer.

Authors:  Hana Hakim; Patricia M Flynn; Katherine M Knapp; Deo Kumar Srivastava; Aditya H Gaur
Journal:  J Pediatr Hematol Oncol       Date:  2009-09       Impact factor: 1.289

5.  Fluoroquinolone prophylaxis in patients with neutropenia: a meta-analysis of randomized placebo-controlled trials.

Authors:  H Imran; I M Tleyjeh; C A S Arndt; L M Baddour; P J Erwin; C Tsigrelis; N Kabbara; V M Montori
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-10-16       Impact factor: 3.267

6.  Skin and soft tissue infections in patients with solid tumours.

Authors:  Diamantis P Kofteridis; Antonios Valachis; Eirini Koutsounaki; Sofia Maraki; Eleni Mavrogeni; Foteini N Economidou; Dimitra Dimopoulou; Kostas Kalbakis; Vassilis Georgoulias; George Samonis
Journal:  ScientificWorldJournal       Date:  2012-02-01

7.  The strategy of antibiotic use in critically ill neutropenic patients.

Authors:  Matthieu Legrand; Adeline Max; Benoît Schlemmer; Elie Azoulay; Bertrand Gachot
Journal:  Ann Intensive Care       Date:  2011-06-15       Impact factor: 6.925

Review 8.  Oral versus intravenous antibiotic treatment for febrile neutropenia in cancer patients.

Authors:  Liat Vidal; Itsik Ben Dor; Mical Paul; Noa Eliakim-Raz; Ellisheva Pokroy; Karla Soares-Weiser; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2013-10-09

9.  Evaluation of febrile neutropenic episodes in adult patients with solid tumors.

Authors:  Oktay Yapici; Filiz Gunseren; Hafize Yapici; Alparslan Merdin; Ülkü Üser Yaylali; Fatma Avci Merdin
Journal:  Mol Clin Oncol       Date:  2015-12-28

Review 10.  Management of infections in critically ill returning travellers in the intensive care unit-II: clinical syndromes and special considerations in immunocompromised patients.

Authors:  Jordi Rello; Oriol Manuel; Philippe Eggimann; Guy Richards; Christian Wejse; Jorgen Eskild Petersen; Kai Zacharowski; Hakan Leblebicioglu
Journal:  Int J Infect Dis       Date:  2016-04-28       Impact factor: 3.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.